All In Biotech

Drug Trial Radar · NCT06572449

Study to Assess Safety and Effectiveness of Slowly Increasing Dose and Food Effect of KarXT in Participants With Schizophrenia

A Phase 3b, Open-label, Multicenter, Two-Period, Slow-titration and Food Effect Study to Assess the Safety and Efficacy of KarXT in Participants With DSM-5 Schizophrenia

Last checked: Nov 20, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

173

Actual

Start

Oct 28, 2024

Primary completion

Mar 13, 2025

Study completion Mar 13, 2025

Sponsor

Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb companyBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Aug 27, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety and efficacy of slowly increasing dose and food effect of KarXT in adult participants with schizophrenia.

Conditions

  • Schizophrenia

Interventions

  • KarXTDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With TEAEs From First Dose to End of Study Follow up.Time frame: From first dose to end of study follow up (63 days)
  2. Number of Participants With TEAEs at the End of Period 1 and Period 2.Time frame: Period 1 (From first dose to day 28) Period 2 (day 29 to day 56)
  3. Number of Participants With Serious TEAEs at the End of Period 1 and Period 2.Time frame: Period 1 (From first dose to day 28); Period 2 (day 29 to day 56); Overall (63 days)
  4. Number of Participants With TEAEs Leading to Treatment Discontinuation.Time frame: Period 1 (From first dose to day 28); Period 2 (day 29 to day 56); Overall (63 days)
  5. Number of Participants With Pro-cholinergic and Anticholinergic TEAEs.Time frame: Period 1 (From first dose to day 28); Period 2 (day 29 to day 56); Overall (63 days)

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Local Institution - 0002

    Los Alamitos, California

  • Local Institution - 0004

    Riverside, California

  • Local Institution - 0006

    Hollywood, Florida

  • Local Institution - 0005

    Atlanta, Georgia

  • Local Institution - 0003

    Decatur, Georgia

  • Local Institution - 0001

    Marlton, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.